Based on these findings, we postulated that a significant portion of patients with NSCLC (~8.5%) whose tumors are associated with novel oncogenic driver RDAA, should respond to the FDA-approved ALK inhibitors. This evidence concerns the gene ALK and non-small cell lung carcinoma.